HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

LY2109761

a transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
Networked: 52 relevant articles (11 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Datta, Pran K: 3 articles (01/2021 - 05/2009)
2. Olinga, Peter: 3 articles (11/2020 - 01/2017)
3. Huber, Peter E: 3 articles (07/2012 - 06/2011)
4. Lahn, Michael: 3 articles (07/2012 - 06/2011)
5. Peschke, Peter: 3 articles (07/2012 - 06/2011)
6. Timke, Carmen: 3 articles (07/2012 - 06/2011)
7. Wirkner, Ute: 3 articles (07/2012 - 06/2011)
8. Yingling, Jonathan M: 3 articles (03/2012 - 05/2010)
9. Antonaci, Salvatore: 3 articles (07/2011 - 10/2009)
10. Fransvea, Emilia: 3 articles (07/2011 - 10/2009)

Related Diseases

1. Neoplasms (Cancer)
2. Neoplasm Metastasis (Metastasis)
3. Carcinoma (Carcinomatosis)
4. Hypertrophic Cicatrix (Hypertrophic Scar)
5. Breast Neoplasms (Breast Cancer)

Related Drugs and Biologics

1. Therapeutic Uses
2. Proteins (Proteins, Gene)
3. Phosphotransferases (Kinase)
4. Transforming Growth Factor beta Receptors (TGF beta Receptors)
5. Luciferases
6. RNA (Ribonucleic Acid)
7. Oxaliplatin (Eloxatin)
8. Erlotinib Hydrochloride (CP 358,774)
9. Vx-11e
10. Transforming Growth Factor beta (TGF-beta)

Related Therapies and Procedures

1. Therapeutics
2. Radiotherapy
3. Drug Therapy (Chemotherapy)
4. Aftercare (After-Treatment)